A recent study suggests that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who stop conventional diet and exercise regimens.
Research printed in a prominent health publication demonstrates that while overweight individuals frequently drop about a fifth of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month after stopping.
"Individuals buying such drugs need to be informed of the potential of fast rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight in about 18 months.
Weighing Approaches
The research, which looked at 37 of studies involving over 9,000 of patients, compared the results of these new drugs with conventional dieting.
Researchers note that people who lose weight through lifestyle changes alone typically see a less rapid weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors suggest the mechanism of the drugs is key to understanding the heightened rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Long-term administration of GLP-1 levels several times higher than normal might result in the system to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Issue?
The NHS suggest the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians say that, given the high risk of weight regain, the treatment should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the persistent nature of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the medication report a intense return of cravings.
"I experienced a trigger activating and I was suddenly ravenous," recalled one woman.
This difficulty is compounded if patients have not established sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent fix and maintained weight loss hinges on ongoing behavioural management.
